SER-287
- Generic Name
- SER-287
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
SER-287 comprises healthy microbiome-derived Gram positive bacterial spores.
- Associated Conditions
- -
- Associated Therapies
- -
Seres Therapeutics, Inc. (MCRB) Stock Price, News, Quote
Seres Therapeutics, Inc. focuses on developing microbiome therapeutics to treat diseases by modulating the colonic microbiome. Its lead product, VOWST, targets recurrent Clostridioides difficile infection, with other candidates in various clinical trial phases for gastrointestinal infections and ulcerative colitis. The company collaborates with NHSc Rx License GmbH and Nestlé for product development and commercialization.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath